Healthcare cybersecurity · IoMT & clinical device risk
Cynerio
Cynerio is a healthcare cybersecurity product for IoMT and clinical device risk. Hospitals use it to see infusion pumps, imaging gear, and monitors on the network and to prioritize what to fix. It is aimed at device-heavy hospitals, not small ambulatory clinics.
Strong fit
- Health systems with large connected device inventories across infusion, imaging, and monitoring
- CISO teams that need clinical-context vulnerability prioritization
- Networks still flat between biomedical and IT segments
Weak fit
- Ambulatory groups with minimal IoMT footprint
- Buyers who only need endpoint EDR on managed laptops
- Organizations unwilling to engage biomed and clinical engineering in the rollout
Bottom line
Cynerio is a Recommend for hospitals that finally admit infusion pumps and imaging gear are on the network — and exploitable. Outcomes hinge on asset visibility and risk prioritization clinicians will accept; the product is strong in IoMT context. Implementation needs biomed partnership, not just a SOC license. Pricing sits in specialized healthcare security territory.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Cynerio is a Recommend for hospitals that finally admit infusion pumps and imaging gear are on the network — and exploitable. Outcomes hinge on asset visibility and risk prioritization clinicians will accept; the product is strong in IoMT context. Implementation needs biomed partnership, not just a SOC license. Pricing sits in specialized healthcare security territory.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Cynerio | 7.3 | 7.0 |
| Claroty | 7.5 | 7.1 |
| Asimily | 7.2 | 6.8 |
| Imprivata | 7.8 | 7.4 |
Pricing
| Item | Detail |
|---|---|
| Model | Typically scaled to beds, sites, or discovered device counts. |
| What usually drives cost | Network sensor hardware and professional services. |
| What to ask in diligence | Total cost of ownership against the cost of a clinical device outage, not against consumer antivirus pricing. |
| Published pricing | Public list price: not published. Expect a custom quote; confirm total cost at your volume. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Cynerio to function | |
| A meaningful IoMT footprint (infusion, imaging, monitoring, similar) | Discovery tools need devices on the network to justify cost. |
| Biomed or clinical engineering as a rollout partner | SOC-only ownership misses device context and change windows. |
| Network access for sensors or traffic visibility | Without visibility into clinical VLANs, asset inventories stay incomplete. |
| A CISO-backed prioritization process clinicians will accept | Vulnerability lists that ignore care impact get ignored. |
| Willingness to segment or remediate after discovery | Finding devices without follow-through is an expensive inventory project. |
| What will maximize your value | |
| Risk rankings tied to clinical location and care impact | Ward context is what makes IoMT prioritization actionable. |
| Joint IT-biomed ticket paths for patches and compensating controls | Split queues recreate the blind spots you are trying to close. |
| Pilot one clinical network zone before hospital-wide sensors | Prove detection quality and false-positive load early. |
| Executive metrics on critical exposed devices over time | Boards fund follow-through when the backlog shrinks visibly. |
| Compare TCO against clinical device outage risk, not consumer antivirus | Wrong price anchors kill useful security programs. |
| Deal-breakers | |
| Ambulatory footprint with minimal connected clinical devices. | |
| You only need endpoint EDR on managed laptops. | |
| Biomed and clinical engineering will not participate. | |
| No appetite to segment or remediate after discovery. | |
| Network teams will not grant required visibility. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Contract signed → kickoff | 3–8 weeks (network design, sensor placement, biomed engagement) |
| 2 | Kickoff → first live workflow | 8–16 weeks for discovery and risk views on a first clinical zone |
| 3 | First live workflow → steady value | 4–9 months of segmentation and remediation habits across sites |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.